FDA officers advocate utilizing Moderna in an emergency as an essential step in direction of approval

Food and Drug Administration officials on Tuesday approved Moderna’s emergency use of the coronavirus vaccine. This is a critical step forward in getting formal approval for public administration as early as next week.

The staff report is designed to brief the FDA’s Advisory Committee on Vaccines and Related Biological Products, which will meet on Thursday to review Moderna’s application for emergency use approval.

The group of outside medical advisors recommended Pfizer’s emergency vaccine last Thursday, and the FDA approved it the next day. The committee is expected to recommend Moderna’s vaccine. The FDA does not need to follow the committee’s recommendation, but it often does.

FDA staff noted that the clinical trial results and safety data “are in line with recommendations in FDA guidelines on approving the emergency use of vaccines to prevent COVID-19.”

“The FDA determined that the sponsor provided adequate information to ensure the quality and consistency of the vaccine for product approval under an EEA,” it said.

According to the announcement, Moderna stock rose 1.5% just before the opening bell.

Moderna is asking the FDA to approve use in people 18 years and older, while Pfizer’s vaccine has been approved for use in people 16 years of age and older. The low data in younger teenagers was a sticking point for the few advisory board members who last week voted against approving the Pfizer vaccine.

The FDA recommends pursuing cases of Bell’s palsy, a condition that causes sudden freezing or weakness in facial muscles, when the vaccine is cleared for use. The agency said there were three cases in the vaccine group and one in the placebo group among the 30,000 study participants. “The information currently available is insufficient to establish a causal link with the vaccine,” the agency wrote.

The most common side effects were injection site pain, fatigue, headache, muscle pain, and chills, according to the FDA. More serious reactions were more common after the second dose. Study participants told CNBC in September that symptoms were uncomfortable and at times very intense. Participants said they often went away after a day, sometimes sooner, and it was better than getting Covid-19.

The FDA said 13 deaths were reported as of December 3, including six in the vaccine group. Two deaths in the vaccine group were people over the age of 75 with pre-existing medical conditions, the agency said. One case was a 72-year-old vaccine recipient with Crohn’s disease and short bowel syndrome who was hospitalized for thrombocytopenia and acute kidney failure.

Moderna submitted its Covid vaccine data to the FDA on November 30th. A final analysis of its Phase 3 clinical trial found the Covid vaccine to be more than 94% effective at preventing, safe and appearing to ward off serious diseases. The vaccine uses messenger RNA or mRNA technology. It’s a new approach to vaccines that uses genetic material to trigger an immune response.

The published documents provide insight into the FDA’s view of the vaccine.

If the FDA approves the vaccine, it will be the second emergency vaccine in the US after the Pfizer BioNTech vaccine. General Gustave Perna, who oversees the logistics for President Donald Trump’s Operation Warp Speed ​​vaccination program, said Monday that the US plans to ship close to 6 million doses of Moderna’s vaccine once the FDA approves emergency use.

Such authorization is not the same as a full approval, which can typically take months longer. Moderna, like Pfizer, only submitted two months of safety data, but the agency typically takes six months for full approval. Pfizer’s vaccine was approved for use in people aged 16 and over.

Moderna, of Cambridge, Massachusetts, announced that its vaccine would remain stable for up to 30 days at 36 to 46 degrees Fahrenheit, the temperature of a regular household or medical refrigerator. It can be stored at minus 4 degrees Fahrenheit for up to six months. In comparison, Pfizer’s vaccine requires a storage temperature of minus 94 degrees Fahrenheit.

The federal government announced last week it would buy another 100 million doses of Moderna’s vaccine. The US reached an agreement with Moderna in August to purchase 100 million cans for about $ 1.5 billion. Moderna said it charged some customers $ 32 to $ 37 per dose for its vaccine at lower “pandemic prices” this month. The company said it was under discussion for larger volume agreements that will have a lower price.

CNBC’s Will Feuer and Noah Higgins-Dunn contributed to this report.

This is a developing story. Please try again.